Latest News Archive

Please select Category, Year, and then Month to display items

UFS scientists part of international COVID-19 study published in peer-reviewed scientific journal

31 July 2020 | Story Andre Damons | Photo Supplied

Burt and Grobler_web read more — Prof Felicity Burt and Prof Paul Grobler from the UFS.

Three scientists from the University of the Free State (UFS), together with authors from other institutions, are part of an international COVID-19 study published in an international peer-reviewed scientific journal recently.

Prof Paul Grobler, Academic Head of Department: Genetics; Prof Felicity Burt, researcher from the Division of Virology, Faculty of Health Sciences and the NHLS, and SARChI (South African Research Chairs Initiative) Research Chair in vector-borne and zoonotic diseases; as well as Prof Trudy Turner from the University of Wisconsin-Milwauwkee, but also an affiliated professor in the Department of Genetics at the UFS, are co-authors of the paper that appeared in Plos One. The study is titled: ACE2 and TMPRSS2 variation in savanna monkeys (Chlorocebus spp.): Potential risk for zoonotic/anthroponotic transmission of SARS-CoV-2 and a potential model for functional studies.

The paper follows an initiative of Prof Chris Schmitt at Boston University with researchers affiliated to the University of California, Los Angeles, Rutgers University, the Polish Academy of Sciences, the Ministry of Health of the Russian Federation, the University of Antwerp, the Wake Forest School of Medicine, and the University of Wisconsin-Milwaukee. The team used the opportunity presented by previously sequenced genomes to screen for variation in the genes associated with susceptibility to infection with SARS-CoV-2.

Concerns about animal welfare and conservation issues

Prof Grobler, who has been studying vervet monkeys from a conservation perspective for two decades, says considering the impact of COVID-19 on the country, he feels that any aspect that might potentially help to understand the progression and transmission of the disease, as well as unexpected risks – however small – should be investigated.

“Since wildlife management is my field, I am of course also concerned about the potential animal welfare and conservation issues involved. It should, however, be emphasised that while SARS-CoV-2 infection in vervet monkeys has now been shown to be genetically possible, there is no proof of it actually happening in the wild yet.”

“I am sure that much work on COVID-19 and vervets will follow internationally, but this is the first study to describe variation at the genes linked to susceptibility,” says Prof Grobler.

Because of his previous work with vervet monkeys in South Africa and further afield, Prof Grobler was invited by Prof Schmitt to contribute to the manuscript.

“I made some suggestions from a conservation perspective, based on my interpretations and also recent international work that have shown that many primate species may be at risk for SARS-CoV-2 infection and are potentially vulnerable to COVID-19. I also felt that some aspects of the paper would be greatly improved with input from a South African expert in zoonotic disease to add to the genetic and conservation perspectives, and I therefore requested that Prof Burt also be approached.”

Potential for non-human primates infection

Prof Burt, whose research interests and expertise include the investigation of viruses of zoonotic origin, and/or those transmitted by mosquitoes and ticks that impact human and/or animal well-being – using a One Health approach – says the study was a collaborative effort between scientists with expertise in a wide range of disciplines, including biological anthropology, genetics, primatology, molecular biology, and virology.

“The concept of One Health encourages collaboration between multiple disciplines, promoting the concept that the interaction between humans, animals, and the environment has an impact on the health of people, animals, plants, and the environment. The outcome is an exciting study that incorporates knowledge from each discipline to investigate the potential susceptibility of non-human primate populations to SARS-CoV-2.”

“The research suggests that there is potential for novel SARS-CoV-2 to infect non-human primates, and that surveillance of non-human primates living in close proximity to human populations is not only warranted, but is actually important for defining risk to both humans and animals,” says Prof Burt.

According to her, the majority of recently emerged viruses, including SARS-CoV-2, were zoonotic in origin. The close proximity of humans and wild non-human primates provides potential for cross-species transmission of pathogens; for some endangered species, this could have devastating effects. Similarly, identifying if non-human primates have the potential to act as intermediate hosts for pathogens with significant public health implications, would be important for understanding zoonotic transmission.

“Novel viruses are continually emerging, and we need to be prepared. A multidisciplinary approach to understanding interactions at the wildlife-human interface will be essential for the prevention of future outbreaks.”

News Archive

Conference: Expanded ARV treatment

2005-03-02

VENUE: University of the Free State, Bloemfontein, South Africa
DATE: 30 March 2005 - 1 April 2005

ARV Programme as on 24Feb Download Word document
Programme Special events Download Word document

Official web site www.fshealth.gov.za/subsites/arvc

Rationale for the Conference
At the time of the planned Conference, much ground would have been covered, both in the Free State and in South Africa, in respect of the expanded public sector ARV treatment programme in respect of research, experiences in practice, training of staff, treatment of patients, lessons learned, successes and failures, etc. The time would then be quite opportune to share these in a systematic manner with other provinces and countries, as well as with the large variety of stakeholders and role players in the ARV and related domains, be they academics and researchers, policy makers and service/facility managers, the variety of caregivers, and the community organisations and affected patients.

The Conference and current research
The proposed Conference is, firstly, directly linked to the current research on the public sector roll-out of ARV treatment in the Free State conducted by several research institutions (e.g. CIET, CHSR&D, UCT Lung Institute). Secondly, the Conference could and would serve as a forum for other research groups in the country and further a field to report and share knowledge and experiences on ARV treatment and related initiatives. Lastly, the Conference will stage a golden opportunity for researchers and scientists, on the one hand, and policy makers, managers, and caregivers (as knowledge users), on the other hand, to engage in cross-disciplinary discourse on this mutual and topical theme.

Theme of Conference
Expanded ARV treatment in the Free State: sharing experiences

Focus
The focus is primarily on public sector ARV treatment in the Free State, but also initiatives/activities/perspectives of relevance to the Free State elsewhere in the country at large and further a field, as well as relevant ARV initiatives in the public, private, NGO and FBO sectors. Bear in mind, however, that ARV treatment is but part of a much more comprehensive approach to HIV and AIDS. The Conference will, therefore, not narrowly focus on the ARV treatment programme only. The broader context, other relevant dimensions, and a comprehensive approach to the challenges of HIV, AIDS and TB are of equal importance.

The purpose of the Conference
Enhance meaningful exchange, mutual understanding and collaboration among researchers, scientists, policy makers, managers and practitioners in the field of ARV treatment and related fields.

Share experiences in the various spheres of ARV treatment and related spheres (policy, management, practice, research, training, public-private-civil society sectors).

Record, reflect and report on the establishment of the ARV treatment programme in the Free State, and in within the context of the comprehensive HIV/AIDS programme.

Disseminate important research results on ARV treatment and related themes to health policy makers, managers, practitioners, communities and to the research community.

Stimulate discourse among various disciplines and various stakeholders/role players involved in ARV treatment and related programmes.

Sensitise and acquaint researchers to the requirements of policy makers, managers and practitioners in respect of ARV treatment and related fields.

Facilitate the implementation of research results in ARV treatment policy, programmes and practice.

Dissemination of Conference-related information
Information generated during the Conference could feed into policy, management and practice of ARV treatment, the training accompanying such programme, and the existing body of knowledge. After the Conference the information will be disseminated via the Internet and by scientific and popular publications.

Date and duration
Set for 30 & 31 March & 1 April 2005; to commence at 09:00 on the first day (30 March) and to end at 16:30 (1 April) the third day.

Format and scope of Conference
Alternating plenary, parallel sessions and debates focused on topical issues and interest groups. The Conference will strive to be maximally interactive and participative.

Themes and topics to cover:

Policy, management and health services/practice (various levels and contexts – clinical treatment, information, IT systems, pharmacy, laboratories, nutrition)
Research covering all relevant disciplines and diverse dimensions of ARV treatment and related themes
Training and evaluation of training
Patients, communities and civil society organisations
Public, private, NGO, FBO initiatives and partnerships

Emphasis will be on the Free State, however, with of significant involvement from other provinces, SADC countries, and countries further a field. The thrust will be to export lessons and experiences from the Free State, but also to import lessons and experiences from other provinces, countries and sectors.

Presenters
Key presenters from the Free State, other provinces, South Africa, from the private, FBO and NGO sectors, and from several other countries

Delegates
About half of the delegates will be Free State stakeholders and role players (all levels and all contexts). The other half will be role players and stakeholders in the ARV and related fields from other provinces, the national level, and other countries, as well as from the private, public and non-governmental sectors.

Focused workshops
Provision will be made for half-a-day or one-day workshop initiatives on the third day (1 April 2005).

Enquiries
For more information please contact:

Prof Dingie van Rensburg
Centre for Health Systems Research & Development
University of the Free State
PO Box 339
Bloenfontein
SOUTH AFRICA
9300

Contact:
Carin van Vuuren
Conference Organiser
Centre for Health Systems Research & Development
University of the Free State
P.O.Box 339
Bloemfontein
South Africa
9300
Tel +27 (0) 51 401 2181
Fax +27 (0) 51 4480370
Cell 0832932890
e-mail: arvconference.hum@mail.uovs.ac.za

Back

Economic and Management Sciences

Education

Health Sciences

The Humanities

Law

Natural and Agricultural Sciences

Theology and Religion

Open Distance Learning

Business School

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept